(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
8 January 2015 (08.01.2015)

WIPO | PCT

(10) International Publication Number
WO 2015/003122 A2

(51) International Patent Classification:
C07K 16/18 (2006.01) *A61K 45/06* (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:
PCT/US2014/045389

(22) International Filing Date:
3 July 2014 (03.07.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/842,745 3 July 2013 (03.07.2013) US
61/982,611 22 April 2014 (22.04.2014) US

(71) Applicant: **ALDER BIOPHARMACEUTICALS, INC.** [US/US]; 11804 North Creek Parkway South, Bothell, Washington 98011 (US).

(72) Inventors: **LATHAM, John A.**; 2409 10th Avenue, NW, Seattle, Washington 98119 (US). **SMITH, Jeffrey T.L.**; 10270 NE 12th Street, Apt. F307, Bellevue, Washington 98004 (US). **BAKER, Brian**; 6475 NE 135th Place, Kirkland, Washington 98034 (US).

(74) Agents: **TESKIN, Robin L.** et al.; Leclair Ryan, P.C., Intellecutal Property Department, 2318 Mill Road, Suite 1100, Alexandria, Virginia 22314 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: REGULATION OF GLUCOSE METABOLISM USING ANTI-CGRP ANTIBODIES




Figure 1: Blood glucose and plasma insulin levels before and after treatment.

(57) Abstract: The present disclosure provides methods for the prevention or treatment of metabolic disorders. In exemplary embodiments, methods of administering an anti-CGRP antibody are provided, optionally in combination with a second agent, wherein peripheral and/or hepatic glucose utilization is increased, thereby preventing or treating diseases and disorders associated with insulin resistance. Compositions comprising an anti-CGRP antibody are also provided, optionally in combination with a second agent, which are suitable for administration to increase peripheral and/or hepatic glucose utilization and thereby prevent or treat diseases and disorders associated with insulin resistance.

WO 2015/003122 A2

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with sequence listing part of description (Rule 5.2(a))*